Clinical EfficacyThe higher 15 mg/kg dose of solnerstotug showed clinical responses, especially in patients with PD-L1 resistant tumors.
Clinical TrialsSolnerstotug demonstrated safety and a promising progression-free survival rate in a challenging post-CKI setting.
Future DevelopmentTwo planned Phase 2 trials are expected, focusing on patients who have failed anti-PD-L1 treatment, indicating ongoing development and potential future advancements.